Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Philadelphia, Pennsylvania

This page shows live ClinicalTrials.gov search results for Philadelphia, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
17147
Shown on this page
12
Current sort
Recently updated
Location scope
Philadelphia, PA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Philadelphia, Pennsylvania. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 721–732 of 17,147 matching trials in Philadelphia, PA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Philadelphia

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Conditions
Hematologic Cancer
Interventions
ABBV-101
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • Palo Alto, California + 11 more
Conditions
Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
RP2, 5-Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel, Pegfilgrastim, Filgrastim, Surgical Resection of Primary Tumor
Biological · Combination Product · Drug + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Interventions
Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
85
States / cities
Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 67 more
Conditions
Myositis
Interventions
Nipocalimab, Placebo, Glucocorticoids
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more
Conditions
Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma
Interventions
Abemaciclib, Biopsy Procedure, Biospecimen Collection, Olaparib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 22 more
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Bevacizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
604
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 426 more
Conditions
Corneal Ulcer
Interventions
Mesenchymal Stromal Cells, Control Solution
Biological · Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Oleclumab, Monalizumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,051 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
33
States / cities
San Diego, California • New Haven, Connecticut • Stuart, Florida + 28 more
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Pembrolizumab, IO102-103
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 2 more
Conditions
Amyotrophic Lateral Sclerosis ALS
Interventions
β-hydroxy-β-methylbutyrate (HMB)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Conditions
Crohn's Disease
Interventions
Guselkumab, Golimumab, JNJ-78934804, Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
90
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more
Conditions
Ulcerative Colitis, Obesity or Overweight
Interventions
Mirikizumab, Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
Dothan, Alabama • Anaheim, California • Beverly Hills, California + 30 more